Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Neoplasms Clinical Trial

Official title:

A Phase 1 Study of Copanlisib(Phosphatidylinositol-3 Kinase Inhibitor) in Combination With Gemcitabine (Treatment A) or Cisplatin Plus Gemcitabine (Treatment B) in Subjects With Advanced Solid Malignancy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01460537
• Other study ID #: 12875
• Status: Completed
• Phase: Phase 1
• First received: September 15, 2011
• Last updated: October 2, 2017
• Start date: November 18, 2011
• Est. completion date: December 18, 2015

Study information

• Verified date: October 2017
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This open label Phase I study involves treating subjects with advanced cancer with Copanlisib in combination with either gemcitabine or cisplatin plus gemcitabine. It will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of Copanlisib in combination with gemcitabine and Copanlisib in combination with cisplatin and gemcitabine. The trial will involve multiple participating sites from the US. Up to a maximum of 70 subjects will be enrolled in the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 18, 2015
• Est. primary completion date: July 20, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects, at least 18 years of age, with advanced or refractory solid tumors in whom gemcitabine (Treatment A) or cisplatin plus gemcitabine (Treatment B) is appropriate medical therapy as determined by the treating physician

• Histological or cytological documentation of non-hematologic, malignant solid tumor, excluding primary brain or spinal tumors, with no current involvement in the CNS

• At least one measurable lesion or evaluable disease, as per RECIST 1.1

• Eastern Cooperative Oncology Group (ECOG) Performance Status Assessment of 0 or 1

• Life expectancy of at least 12 weeks

• Alanine aminotransferase (ALT) = 3.0 x upper limit of normal (ULN; =5 x ULN for subjects with liver involvement with cancer)

• Aspartate aminotransferase (AST) = 3.0 x ULN (= 5 x ULN for subjects with liver involvement with cancer)

• Total bilirubin = 2.0 x ULN

• Serum creatinine = 1.5 x ULN

• Prothrombin time-international normalized ratio/partial thromboplastin time (PT-INR/PTT) < 1.5 x ULN (Subjects who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists). Low-dose aspirin is permitted (= 100 mg daily).

Exclusion Criteria:

• History of cardiac disease congestive; congestive heart failure > New York Heart Association functional classification system (NYHA) Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset angina within 3 months prior to study entry or unstable angina, or ventricular cardiac arrhythmias requiring anti-arrhythmic therapy

• Current diagnosis of Type 1 or 2 diabetes mellitus, hyperglycemia (defined as consistent fasting blood glucose > 125 mg/dL) or HgBA1c = 7%

• Use of systemic corticosteroids within 2 weeks of the start of study treatment (topical or inhaled steroids are permitted). Single doses of systemic corticosteroids given as premedication for procedures or non-study drugs may be administered up to 24 hours of first dosing of Copanlisib.

• Poorly controlled hypertension, defined as systolic blood pressure (BP) > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management

• Poorly controlled seizure disorder

• Subjects undergoing renal dialysis

• Use of strong inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir, nefazodone and saquinavir) and strong inducers of CYP3A4 (eg, rifampin) are not permitted from Day -14 of Cycle 1 and for the duration of the study.

• Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of first study treatment

• Hormonal therapy during the study or within 2 weeks of first study treatment.

• Bisphosphonate therapy during the first 2 cycles of treatment

• Biological response modifiers, such as granulocyte colony stimulating factor (G-CSF) within 4 weeks of first study treatment

• Radiotherapy to target lesions during study or within 4 weeks of first study treatment

• Known hypersensitivity to the study drugs or active substances or excipients of the preparations

• Use of St John's Wort is prohibited from Day -14 and for the duration of the study

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• Gemcitabine
Gemcitabine 1000mg/m2 as 30-minutes IV infusion
• BAY80-6946
Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
• Cisplatin
1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
• NaCl
Infusion of 500 ml of 0.9% NaCl over 30-minutes
• BAY80-6964 fixed dose
BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse event collection		Up to 3 years or longer if indicated
Primary	Maximum tolerated dose, measured by adverse event profile		Up to 3 years or longer if indicated
Secondary	Maximum drug concentration in plasma (Cmax) of Copanlisib with gemcitabine or cisplatin plus gemcitabine		Approximately 18 months
Secondary	The time of the maximum concentration (Tmax) of Copanlisib with gemcitabine or cisplatin plus gemcitabine		Approximately 18 months
Secondary	Area under the curve (AUC) of Copanlisib with gemcitabine or cisplatin plus gemcitabine		Approximately 18 months
Secondary	Area under the concentration time curve (AUC (0-tn)) of Copanlisib with gemcitabine or cisplatin plus gemcitabine		Approximately 18 months
Secondary	Half life (t1/2) of Copanlisib with gemcitabine or cisplatin plus gemcitabine		Approximately 18 months
Secondary	Biomarker evaluation including analysis of pathway activation in tumor tissue and blood/plasma		Up to 3 years or longer if indicated
Secondary	Tumor Response as measured by RECIST 1.1 criteria		Up to 3 years or longer if indicated

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find results for studies related to Bayer products.